• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Down Over 200 Points; US Job Openings Rise In August

    10/3/23 12:20:53 PM ET
    $FEMY
    $LLY
    $OCEA
    $PNT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FEMY alert in real time by email

    U.S. stocks extended losses midway through trading, with the Nasdaq Composite falling more than 200 points on Tuesday.

    The Dow traded down 1.06% to 33,078.27 while the NASDAQ fell 1.60% to 13,094.83. The S&P 500 also fell, dropping, 1.27% to 4,233.76.

    Check This Out: Vivani Medical And 3 Other Stocks Under $2 Insiders Are Buying

     

    Leading and Lagging Sectors

    Materials shares fell by just 0.1% on Tuesday.

    In trading on Tuesday, consumer discretionary shares dipped by around 2%.

     

    Top Headline

    The number of job openings increased by 690,000 from the prior month to 9.61 million in August, compared to market estimates of 8.8 million.

     

    Equities Trading UP

    Vericity, Inc. (NASDAQ:VERY) shares shot up 87% to $11.06 after iA Financial Group announced it will acquire the company.

    Shares of POINT Biopharma Global Inc. (NASDAQ:PNT) got a boost, shooting 85% to $12.39. Eli Lilly And Co (NYSE:LLY) agreed to acquire POINT Biopharma Global at $12.50 per share in cash, an aggregate of approximately $1.4 billion.

    SciSparc Ltd. (NASDAQ:SPRC) shares were also up, gaining 33% to $4.8839 after the company announced it was granted a European patent for its core technology.

     

    Equities Trading DOWN

    SmileDirectClub, Inc. (NASDAQ:SDC) shares dropped 42% to $0.0932 after the company reported it received notice that its securities will be delisted from the Nasdaq.

    Shares of Ocean Biomedical, Inc. (NASDAQ:OCEA) were down 26% to $2.5850 as the company said its cancer-targeting immunotherapy antibody candidate demonstrated effective tumor reduction against an aggressive subset of Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor mutations.

    Femasys Inc. (NASDAQ:FEMY) was down, falling 36% to $2.4998 after gaining more than 30% on Monday.

    Also Check This Out: Wall Street's Most Accurate Analysts Say Hold These 3 Real Estate Stocks With Over 7% Dividend Yields

     

    Commodities

    In commodity news, oil traded up 1.5% to $90.13 while gold traded down 0.3% at $1,842.90.

    Silver traded up 0.4% to $21.51 on Tuesday while copper fell 0.3% to $3.6290.

     

    Euro zone

    European shares were lower today. The eurozone’s STOXX 600 fell 1.1% London’s FTSE 100 fell 0.54% while Spain’s IBEX 35 Index fell 1.65% The German DAX fell 1.06% French CAC 40 fell 1.01%, while Italy’s FTSE MIB Index fell 1.32%.

    French government budget deficit rose to EUR 187.9 billion in January to August 2023, compared to EUR 149.9 billion in the year-ago period.

     

    Asia Pacific Markets

    Asian markets closed lower on Tuesday, with Japan’s Nikkei 225 falling 1.64% and Hong Kong’s Hang Seng Index lost 2.69%. India’s S&P BSE Sensex, meanwhile, fell 0.5%.

    The S&P Global Indian manufacturing PMI fell to 57.5 in September from 58.6. The Reserve Bank of Australia maintained its cash rate at 4.1%. The value of new home loans for owner-occupied homes in Australia rose by 2.6% month-over-month to A$ 16.07 billion during August, while job advertisements slipped by 0.1% month-over-month in September.

     

    Economics

    The Logistics Manager’s Index rose to 52.4 in September.

    The IBD/TIPP Economic Optimism Index fell to 36.3 in October from September's reading of 43.2.

    The number of job openings increased by 690,000 from the prior month to 9.61 million in August.

    Now Read This: Top 2 Energy Stocks That Could Sink Your Portfolio This Quarter

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 108,758,600 cases with around 1,177,280 deaths. India confirmed a total of at least 44,998,830 cases and 531,930 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 696,038,990 cases of COVID-19 worldwide with more than 6,921,810 deaths.

    Get the next $FEMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FEMY
    $LLY
    $OCEA
    $PNT

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Eli Lilly and Company
    $LLY
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    Eli Lilly and Company
    $LLY
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    Eli Lilly and Company
    $LLY
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Eli Lilly and Company
    $LLY
    11/13/2025$1165.00Sector Outperform
    Scotiabank
    Eli Lilly and Company
    $LLY
    11/10/2025$1104.00Market Perform → Outperform
    Leerink Partners
    Eli Lilly and Company
    $LLY
    10/20/2025$840.00 → $930.00Outperform
    BMO Capital Markets
    More analyst ratings

    $FEMY
    $LLY
    $OCEA
    $PNT
    SEC Filings

    View All

    SEC Form 6-K filed by SciSparc Ltd.

    6-K - SciSparc Ltd. (0001611746) (Filer)

    2/4/26 4:01:15 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ELI LILLY & Co (0000059478) (Filer)

    2/4/26 7:05:22 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-3 filed by SciSparc Ltd.

    F-3 - SciSparc Ltd. (0001611746) (Filer)

    2/3/26 4:36:47 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Finance, & CAO Zakrowski Donald A was granted 584 shares, increasing direct ownership by 21% to 3,423 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:27:28 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP&Pres, LLY USA&Global Capab Yuffa Ilya was granted 4,163 shares, increasing direct ownership by 15% to 32,304 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:26:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Pres LLY Oncology&HdCorpBD Van Naarden Jacob was granted 4,866 shares, increasing direct ownership by 22% to 26,626 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:25:13 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Eli Lilly with a new price target

    UBS resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $1,250.00

    1/7/26 9:11:47 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Eli Lilly from Neutral to Buy and set a new price target of $1,230.00

    12/16/25 8:49:23 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman reiterated coverage on Eli Lilly with a new price target

    Goldman reiterated coverage of Eli Lilly with a rating of Buy and set a new price target of $1,145.00 from $951.00 previously

    12/15/25 10:37:03 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $FEMY
    $LLY
    $OCEA
    $PNT
    Financials

    Live finance-specific insights

    View All

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

    INDIANAPOLIS, Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.   The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into h

    1/21/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly declares first-quarter 2026 dividend

    INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discov

    12/8/25 2:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Vericity Inc.

    SC 13D/A - Vericity, Inc. (0001575434) (Subject)

    7/2/24 5:04:34 PM ET
    $VERY
    Life Insurance
    Finance

    SEC Form SC 13G filed by SciSparc Ltd.

    SC 13G - SciSparc Ltd. (0001611746) (Subject)

    3/6/24 5:02:18 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care